| Home | About DNDi | Diseases and Projects | Treatments | Advocacy | News | Support DNDi |
Encouraging Development of Therapeutics for Neglected Diseases
Conference, March 12-13, 2012, Philadelphia, PA
Conference title: Encouraging Development of Therapeutics for Neglected Diseases
On Day 1 of the conference (Monday, March 12), 9:35 AM, DNDi Business Development Director Jean-Pierre Paccaud spoke about collaborations between product development partnerships (PDPs), such as DNDi, with the pharmaceutical industry, for global public health needs and goals.
Presentation title: "The Future of Industry-PDP Collaborations: Integrating Global Health into New Pharma Business Model?"
Summary: The emergence of PDPs developing new treatments and vaccines against neglected tropical diseases provides hope for millions of patients awaiting life saving therapeutics the industry failed to develop because of the lack of a market. Although it took PDPs several years to succeed in involving industry into their activities, today most pharma companies advertise their relationship with one or several PDPs. Most of the collaborations are still at the discovery or pre-clinical stage, where pharma involvement does not generate significant costs for the industry. PDPs have demonstrated various achievements in R&D, developing products or vaccines with the help of their industrial collaborations, but they may face difficult challenges when it comes to industrial manufacturing, registration and distribution if they are not backed up by a strong industrial partner. At this stage, will industry be willing to engage in insuring sustainable drug/vaccine delivery at conditions enabling the neglected patients to access the drug? What can be the alternatives? What framework would be favorable for continued private sector involvement?